Scientists train immune cells to hunt down mutated blood cancers
NCT ID NCT06904066
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if this approach is safe and feasible, and whether it can shrink tumors. The study is currently recruiting 86 participants aged 18 to 75.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized T cells (neoantigen-specific T cells) plus chemotherapy drugs (cyclophosphamide, fludarabine) and aldesleukin
What this could lead to
If successful, this could point toward a new personalized treatment for hard-to-treat blood cancers by training the immune system to attack cancer cells with specific mutations.
What could go wrong
This is a very early phase 1 trial with only 86 participants, so it is primarily testing safety and feasibility. The treatment is complex and individualized, and it may not work for everyone or may cause serious side effects from the chemotherapy and cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••